tradingkey.logo

BUZZ-BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating

ReutersFeb 25, 2025 12:42 PM

BofA Global Research starts coverage on insulin device maker Beta Bionics BBNX.O with "buy" rating and $25 PT, citing its "differentiated closed-loop algorithm" that simplifies insulin-dosing for diabetic patients

PT represents a 21.4% upside to stock's last close

Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years

Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA

Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026

Stock has fallen 12.8% since its Nasdaq debut on 30 Jan

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI